Results from the Phase II/III Vibrance-MG study found that patients with generalized myasthenia gravis who were treated with nipocalimab plus standard-of-care achieved sustained disease control.
Results from the Phase II/III Vibrance-MG study found that Johnson & Johnson’s (J&J) nipocalimab demonstrated sustained disease control in adolescents between 12 and 17 years of age with generalized myasthenia gravis (gMG). According to the company, these results suggest that nipocalimab may be a promising treatment option for young patients with the autoimmune disorder.
J&J stated that nipocalimab is the first FcRn blocker to demonstrate sustained disease control in a registrational trial. These data are expected to be presented at the upcoming Myasthenia Gravis Foundation of America Scientific Session during the American Association of Neuromuscular & Electrodiagnostic Medicine annual meeting.1
“Findings from the Vibrance-MG study underscore the potential of this investigational therapy for young individuals aged 12–17 living with gMG. Results show a significant reduction in IgG of approximately 70% in adolescents and a clinical benefit that is consistent with the Vivacity-MG3 study in adults,” said Jonathan Strober, MD, director, clinical services, child neurology, director, Muscular Dystrophy Clinic at UCSF Benioff Children’s Hospital, in a press release. “It is encouraging to see these positive results as there are currently no approved advanced treatment options for this adolescent population in the United States.”
Vibrance-MG is an on-going, open-label study aimed to determine the effect of nipocalimab in pediatric participants with gMG. In order to qualify for the trial, participants must have a positive blood test for either acetylcholine receptor (anti-AChR) muscle-specific tyrosine kinase (anti-MuSK) autoantibodies. During the study, patients will go through a screening period of up to four weeks, followed by a 24-week open-label active treatment phase during which participants receive nipocalimab intravenously every two weeks, and a long-term extension phase. The primary endpoint of the study is the effect of nipocalimab on total serum immunoglobulin G (IgG), safety and tolerability, and pharmacokinetics in pediatric participants with gMG at 24 weeks.
Results found that four out of five patients achieved minimum symptom expression by the end of their treatment phase. Nipocalimab was found to have been well tolerated over a six-month period, similar to tolerability seen in adult participants in the Vivacity-MG3 study. There were no serious adverse events (AEs) reported and no discontinuations due to a serious AE.1
According to the Myasthenia Gravis Foundation of America, an estimated 150 to 200 out of one million people are currently living with myasthenia gravis globally. In the United States, this number is approximately 37 out of every 100,000 people. It is most common in women under 50 years of age and men over 65 years of age. On average, it is most common in people over 50 years of age. While it can affect people of all ethnic backgrounds, it is slightly more common in people of African descent. Additional research has shown that individuals of African American descent could be more likely to develop myasthenia gravis at a younger age.2
“The Vibrance-MG data add to the expanding clinical profile of nipocalimab and highlight its potential for adolescents living with gMG who are in need of new treatments,” said Sindhu Ramchandren, MD, executive medical director, neuroscience, Johnson & Johnson Innovative Medicine, in the press release. “We are committed to developing innovations for autoantibody-driven neurological diseases, like gMG, with the aim of transforming the lives of people living with these conditions.”
Earlier in the year, J&J announced the submission of applications to the FDA and EMA seeking approval for nipocalimab for the treatment of gMG.1
References
1. Nipocalimab demonstrates sustained disease control in adolescents living with generalized myasthenia gravis in Phase 2/3 study. J&J. October 15, 2024. Accessed October 16, 2024. https://www.jnj.com/media-center/press-releases/nipocalimab-demonstrates-sustained-disease-control-in-adolescents-living-with-generalized-myasthenia-gravis-in-phase-2-3-study
2. OVERVIEW OF MG. Accessed October 16, 2024. https://myasthenia.org/understanding-mg/overview-mg/#:~:text=Globally%2C%20approximately%20150%20to%20200,million%20people%20have%20myasthenia%20gravis.&text=In%20the%20US%2C%20it%20is,100%2C000%20people%20have%20myasthenia%20gravis.
Key Findings of the NIAGARA and HIMALAYA Trials
November 8th 2024In this episode of the Pharmaceutical Executive podcast, Shubh Goel, head of immuno-oncology, gastrointestinal tumors, US oncology business unit, AstraZeneca, discusses the findings of the NIAGARA trial in bladder cancer and the significance of the five-year overall survival data from the HIMALAYA trial, particularly the long-term efficacy of the STRIDE regimen for unresectable liver cancer.
Cell and Gene Therapy Check-in 2024
January 18th 2024Fran Gregory, VP of Emerging Therapies, Cardinal Health discusses her career, how both CAR-T therapies and personalization have been gaining momentum and what kind of progress we expect to see from them, some of the biggest hurdles facing their section of the industry, the importance of patient advocacy and so much more.
ROI and Rare Disease: Retooling the ‘Gene’ Value Machine
November 14th 2024Framework proposes three strategies designed to address the unique challenges of personalized and genetic therapies for rare diseases—and increase the probability of economic success for a new wave of potential curative treatments for these conditions.
Tirzepatide Demonstrates Significant Benefits for Patients with Pre-Diabetes, Obesity Over 176 Weeks
November 14th 2024Results from the Phase III SURMOUNT-1 study show that tirzepatide, a dual GIP and GLP-1 receptor agonist, achieved substantial average weight loss of 22.9% in patients with pre-diabetes and obesity.